Anika Therapeutics, Inc. 8-K

What Happened

• On April 29, 2026, Anika Therapeutics, Inc. announced its financial results for the quarter ended March 31, 2026 via a press release (filed as Exhibit 99.1 to the 8-K).
• On April 24, 2026, Board members William R. Jellison (Class I) and Glenn R. Larsen, Ph.D. (Class II) notified the company they will resign from the Board and all committee assignments effective at the company’s 2026 annual meeting of stockholders; the Board accepted both resignations and will reduce its size from nine to seven members. The company stated neither resignation involved any disagreement with management or the Board.

Key Details

• Filing date of the 8-K: April 29, 2026.
• Quarterly period covered: quarter ended March 31, 2026 (Q1 2026); full press release furnished as Exhibit 99.1 and incorporated by reference.
• Resignation notice date: April 24, 2026; resignations effective at the 2026 annual meeting.
• Board size change: will decrease from nine members to seven members following the resignations.

Why It Matters

• The press release provides the company’s latest quarterly results (earnings/revenue/quarterly results) and is the primary source for investors to assess recent financial performance and management commentary—review Exhibit 99.1 for detailed figures and guidance.
• Board departures change company governance composition (nine to seven directors). The filing notes the resignations were not due to disagreements, which is a factual governance detail investors commonly monitor.